ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 487,23
-0,35%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Finch Therapeutics Group Inc (FNCH)

  7. Finch Therapeutics Group Inc (FNCH) Actualités

FNCH

Finch Therapeutics (FNCH)

Finch Therapeutics Group Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:FNCH
DateHeureSourceTitreSymboleSociété
24/05/202412h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FNCHFinch Therapeutics Group Inc
10/05/202422h45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:FNCHFinch Therapeutics Group Inc
13/12/202323h20Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:FNCHFinch Therapeutics Group Inc
11/08/202312h31Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:FNCHFinch Therapeutics Group Inc
28/06/202322h31Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:FNCHFinch Therapeutics Group Inc
23/06/202322h31Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:FNCHFinch Therapeutics Group Inc
09/06/202322h53Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:FNCHFinch Therapeutics Group Inc
09/06/202313h00GlobeNewswire Inc.Finch Announces Reverse Stock Split of Common StockNASDAQ:FNCHFinch Therapeutics Group Inc
16/05/202322h17Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:FNCHFinch Therapeutics Group Inc
11/05/202322h13Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:FNCHFinch Therapeutics Group Inc
10/05/202313h15Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:FNCHFinch Therapeutics Group Inc
10/05/202313h00GlobeNewswire Inc.Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdatesNASDAQ:FNCHFinch Therapeutics Group Inc
26/04/202322h05Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:FNCHFinch Therapeutics Group Inc
26/04/202322h02Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:FNCHFinch Therapeutics Group Inc
25/04/202322h05GlobeNewswire Inc.Finch Therapeutics Announces Executive Leadership TransitionsNASDAQ:FNCHFinch Therapeutics Group Inc
18/04/202322h01GlobeNewswire Inc.Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License AgreementNASDAQ:FNCHFinch Therapeutics Group Inc
14/04/202322h08Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:FNCHFinch Therapeutics Group Inc
23/03/202321h25Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:FNCHFinch Therapeutics Group Inc
23/03/202321h05GlobeNewswire Inc.Finch Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesNASDAQ:FNCHFinch Therapeutics Group Inc
24/01/202314h00GlobeNewswire Inc.Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other AssetsNASDAQ:FNCHFinch Therapeutics Group Inc
10/11/202213h00GlobeNewswire Inc.Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial ResultsNASDAQ:FNCHFinch Therapeutics Group Inc
09/11/202214h00GlobeNewswire Inc.Finch Therapeutics to Present at the Jefferies London Healthcare Conference and Evercore ISI HealthCONx ConferenceNASDAQ:FNCHFinch Therapeutics Group Inc
24/10/202214h00GlobeNewswire Inc.Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile InfectionNASDAQ:FNCHFinch Therapeutics Group Inc
01/09/202214h00GlobeNewswire Inc.Finch Therapeutics Provides Business UpdateNASDAQ:FNCHFinch Therapeutics Group Inc
25/08/202222h30GlobeNewswire Inc.Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBDNASDAQ:FNCHFinch Therapeutics Group Inc
11/08/202213h00GlobeNewswire Inc.Finch Therapeutics Provides Corporate Updates and Reports Second Quarter 2022 Financial ResultsNASDAQ:FNCHFinch Therapeutics Group Inc
03/06/202212h03Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:FNCHFinch Therapeutics Group Inc
02/06/202213h00GlobeNewswire Inc.Finch Therapeutics to Participate in Upcoming June Investor ConferencesNASDAQ:FNCHFinch Therapeutics Group Inc
17/05/202214h00GlobeNewswire Inc.Finch Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceNASDAQ:FNCHFinch Therapeutics Group Inc
16/05/202213h00GlobeNewswire Inc.Finch Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial ResultsNASDAQ:FNCHFinch Therapeutics Group Inc
 Showing the most relevant articles for your search:NASDAQ:FNCH

Dernières Valeurs Consultées

BIT
P17XJ0
BNP Paribas Issuance
BIT
S27677
Societe Generale Effekten
BIT
Q00415
Leonteq Securities
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés